The Application of Marine Natural Products (MNPS) In Anti-Covid-19 Therapeutics
DOI:
https://doi.org/10.22270/ajprd.v8i6.809Keywords:
Marine, COVID-19, Natural product Mpro, Structural uniqueness.Abstract
The bioprospecting of MNPs for the treatment of COVID-19 virus was attempted. The marine biodiversity is a remarkable source of bioactive chemotherapeuticals. The structural uniqueness of selected MNPs was correlatedwith reported binding energies to ascertain structure activity relationship (SAR) features.
Downloads
References
2. Mayer, A. M.; Rodriguez, A. D.; Berlinck, R. G.; Fusetani, N., Marine pharmacology in 2007-8: Marine compounds with antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the immune And nervous system, and other miscellaneous mechanisms of action. Comp Biochem Physiol C Toxicol Pharmacon 2011; 153:191-222.
3. Park, J. Y. Kim, J. H.; Kwon, J. M.; Kwon, H. J.; Jeong, H. J.; Kim, Y. M.; Kim, D.; Lee, W. S.; Ryu, Y. B., Dieckol, a SARS-CoV 3CL(pro) inhibitor, isolated from the edible brown algae Ecklonia cava. Bioorg Med Chem 2013; 21:3730-3737.
4. Liu, L.; Heinrich, M.; Myers, S.’ Dworjanyn, S. A., Towards a better understanding of medicinal uses of the brown seaweed Sargassum in Traditional Chinese Medicine: a phytochemical and pharmacological review. J Ethnopharmacol 2012; 142:591-619.
5. Li, y.; Fu, X.; Duan, D.; Liu, X.; Xu, J.; Gao, X., Extraction and Identification of Phlorotannins from the Brown Alga, Sargassumfusiforme (Harvey) Setchell. Mar Drugs 2017; 15.
6. Nakao, Y.; Masuda, A.; Matsunaga, S.; Fusetani, N., Pseudotheonamides, serine protease inhibitors from the marine sponge Theonellaswinhoei. J. Am. Chem. Soc. 1999; 121:2425-2431.
7. Glombitza, K. W.; Keusgen, M., Fuhalols and Deshydroxyfuhalols from the Brown Alga Sargassum-Spinuligerum. Phytochemistry 1995; 38:987-995.
8. Yang. S. y., Pharmacophoremodeling and applications in drug discovery: challenges and recent advances. Drug Discov Today 2010; 15, 444-450.
9. Jin, Z.; Du, X.; Xu, Y.; Deng, Y.; Liu, M.; Zhao, Y.; Zhang, B.; Li, X.; Zhang, L,; Peng, C.; Duan, Y.; Yu, J.; Wang, L.; Yang, K.; Liu, F.; Jiang, R.; Yang, X.; You, T.; Liu, X.; Yang, X.; Bai, F.; Liu, H.; Liu, X.; Guddat, L. W.; Xu, W.; Xiao, G.; Qin, C.; Shi, Z.; Jiang, H.; Rao, Z.; Yang, H., Structure of Mpro from COVID-19 virus and discovery of its inhibitors. bioRxiv, 2020; 2002.2026.964882.
Published
How to Cite
Issue
Section
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).